Comparative Pharmacology
Head-to-head clinical analysis: MINTEZOL versus PIPERAZINE CITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINTEZOL versus PIPERAZINE CITRATE.
MINTEZOL vs PIPERAZINE CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiabendazole inhibits the mitochondrial fumarate reductase system in susceptible helminths, disrupting energy metabolism.
Piperazine citrate acts as a gamma-aminobutyric acid (GABA) receptor agonist in nematodes, causing hyperpolarization of nerve membranes and flaccid paralysis of the worm, which is then expelled by normal peristalsis. It does not affect mammalian neuromuscular junctions due to differences in GABA receptor sensitivity.
50 mg/kg/day orally in 2-3 divided doses, maximum 3 g/day, for 2-3 days.
Adults: 3.5 g orally once daily for 2 days; may repeat after 1 week if needed.
None Documented
None Documented
Terminal elimination half-life: 2-8 hours (mean 4 hours). Hepatic impairment prolongs; dose adjustment recommended.
Terminal elimination half-life: 2-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Renal: 90% within 24 hours (5% unchanged, 85% as metabolites). Fecal: <10%.
Primarily renal (60-70% unchanged); biliary/fecal elimination accounts for 10-20% of the dose.
Category C
Category C
Anthelmintic
Anthelmintic